Step Pharma SAS

https://www.step-ph.com

Step Pharma is focused on the development of a novel class of oral nucleotide synthesis inhibitors targeting CTPS1 for the improved treatment of a range of oncology and autoimmune diseases. The company has identified several inhibitors of CTPS1, with the most advanced, STP938 being prepared for clinical studies in T-cell malignancies. Step Pharma was founded in June 2014 by Kurma Partners, the Imagine Institute, and Sygnature Discovery based on the scientific discoveries of Prof. Alain Fischer and Dr Sylvain Latour’s laboratory at the Imagine Institute, Paris. Step Pharma is based in Archamps, France. *

	Start	2014-06-01 established
	Industry	CTPS1 inhibitor
	Industry 2	drug development
	Person	Parker, Andrew (Step Pharma 201909– CEO before Zealand Pharma + Eclosion2 + AstraZeneca + JnJ + Opsana Therapeutics)

	Street	218 avenue Marie Curie Forum 2
	City	74160 Archamps
	Tel	+33-7-8154-8061
		Address record changed: 2021-03-25

Basic data	Employees	n. a.

		* Document for »About Section«: Step Pharma SAS. (3/24/21). "Press Release: Step Pharma Raises EUR35 Million in Series B Financing to Advance First in Class CTPS1 inhibitor into the Clinic in T Cell Malignancies". Archamps.

		Record changed: 2024-03-30

Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x200px

More documents for Step Pharma SAS

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)